CD38 and acute myeloid leukemia: Initially, this technique was used in primary NK cells to disrupt the CD38 gene, aiming to prevent fratricide of NK cells when they were used in combination with daratumumab (anti-CD38), as CD38 is expressed both on NK cells and multiple myeloma and AML cells [104].